Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.49 |
| ▸ | TUBB | P07437 | 2/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.49 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.49 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.49 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.49 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.49 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.49 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.49 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.49 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.49 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL970447 | 0.85 | RXFP1 (0.50) | ALDH1A1MAPTLMNATPMTTSHR | |
| SCHEMBL7376402 | 0.85 | TUBB4A (0.51) | ABCG2TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL257441 | 0.84 | MLYCD (0.41) | ABCG2ALDH1A1MAPTLMNAMAPK1 | |
| SCHEMBL15100737 | 0.84 | MLYCD (0.41) | ALDH1A1MAPTLMNATPMTTSHR | |
| SCHEMBL1436447 | 0.83 | TUBB4A (0.50) | ABCG2TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL1190257 | 0.80 | TDP1 (0.53) | ALDH1A1MEN1KMT2AKDM4EGAA | |
| SCHEMBL31419843 | 0.80 | ALDH1A1 (0.53) | ALDH1A1LMNATPMTMEN1KMT2A | |
| SCHEMBL30807980 | 0.80 | TPMT (0.49) | ALDH1A1MAPTLMNATPMTTSHR | |
| SCHEMBL26709446 | 0.80 | LMNA (0.42) | TUBB1LMNAMAPK1TPMTNFKB1 | |
| SCHEMBL31346688 | 0.80 | ALOX5 (0.51) | TUBB1ALDH1A1LMNAMAPK1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553075-B1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-2565178-A1 | LPA Receptor Antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-8124645-B2 | LPA receptor antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| EP-1695955-B1 | COMPOUNDS HAVING LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISM AND USES THEREOF | ONO PHARMACEUTICAL CO (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-7875745-B2 | {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4- methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid; for urinary system disease selected from the group of prostatic hypertrophy, neurogenic bladder dysfunction disease, dysuria, pollakiuria, night urination and urodynia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| US-7820682-B2 | LPA receptor antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20100249157-A2 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20080293764-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. | 2008-11-27 | — | — | US | disclosed |
| US-20070149595-A1 | Compounds having lysophosphatidic acid receptor antagonism and uses thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-0476658-B1 | 1-Phenyl-3-phenyl-2-propyne-1-ones | MERRELL DOW PHARMA (US) | 1995-11-15 | — | — | EP | disclosed |
| US-5446068-A | Antiinflammatory agent | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-08-29 | — | — | US | disclosed |
| US-5382670-A | Platelet activating factor antagonists | ABBOTT LABORATORIES (US) | 1995-01-17 | — | — | US | disclosed |
| EP-0574494-A4 | INDOLES USEFUL AS PLATELET ACTIVATING FACTOR ANTAGONISTS | ABBOTT LAB (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0574494-A1 | INDOLES USEFUL AS PLATELET ACTIVATING FACTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1993-12-22 | — | — | EP | disclosed |
| US-5248825-A | Aromatic ketones containing triple bond | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-09-28 | — | — | US | disclosed |
| WO-1992014732-A1 | INDOLES USEFUL AS PLATELET ACTIVATING FACTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1992-09-03 | — | — | WO | disclosed |
| EP-0499987-A1 | Platelet activating factor antagonists | ABBOTT LABORATORIES (US) | 1992-08-26 | — | — | EP | disclosed |
| EP-0476658-A1 | 1-Phenyl-3-phenyl-2-propyne-1-ones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-03-25 | — | — | EP | disclosed |
| US-4929741-A | ANTISECRETORY AGENTS, GASTRIC JUICE, ANTIULCER AGENTS | HOFFMAN-LA ROCHE INC. (US) | 1990-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293764-A1 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | ABCG2 1746/4885TUBB1 2339/4885TUBB4A 2712/4885 |
| US-20100249157-A2 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | ABCG2 1746/4885TUBB1 2339/4885TUBB4A 2712/4885 |
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | ABCG2 1746/4885TUBB1 2339/4885TUBB4A 2712/4885 |
| US-20070149595-A1 | Compounds having lysophosphatidic acid receptor antagonism and uses thereof | LPAR2, LPAR1, LPAR5 | ABCG2 4084/4885TUBB1 4694/4885TUBB4A 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.